Title

Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia
Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia.
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Study Participants

    161
The purpose of this study is to determine if isotonic solutions reduce the risk of hospital acquired hyponatremia compared with hypotonic solutions.
Multicenter, Randomized, Controlled clinical trial.

The purpose of this study is to determine if isotonic solutions reduce the risk of hospital acquired hyponatremia compared with hypotonic solutions

This study will include 150 patients in 2 groups according to these type of pathology: group 1: medical conditions which includes respiratory problems (pneumonia, bronchiolitis, acute asthma attack) and acute gastrointestinal problems (bacterial or viral gastroenteritis) and group 2: surgical conditions (pre, peri or postoperative patients will be included). Each group will be randomized to receive 3 types of interventions: 0.3% Saline (hypotonic solution), 0.45% Saline (hypotonic solution) or 0.9% Saline (isotonic solution). In non-dehydrated patients the daily total volume of liquid infused will be determined by the volumetric Holliday- Segar* formula and the daily total volume will be calculated by adding the maintenance requirements (using the Holliday Segar formula) to the fluid deficit (according to percent of estimated weight**) in dehydrated patients.

The glucose concentrations in the first group will be 3.3%, and in group 2 and 3 will be 5%. The potassium concentration will be 20mEq/L in all groups. Blood samples will be collected before, 8 hours and 24 hours after the start of intravenous fluid, for the analysis of sodium, potassium, glucose, urea and creatinine. The adverse clinical outcomes at 8 and 24 hours of the start of intravenous fluid will also be recorded. The sodium plasma level, the incidence of hyponatremia and the adverse clinical outcomes will be compared.

*0-10 kilogram (kg): 100ml/kg per day; 10-20 kg: 1000 ml + 50 ml/kg/day over 10 kg; >20 kg: 1500 ml + 20ml/ kg over 20kg

** In patients under 10 kg correspond to a loss of 5% (50 mL/kg) in mild dehydration and 10% in moderate dehydration. In 10 kg or more: 3% (30 mL/kg) in mild dehydration and 6% (60 mL/kg) in moderate dehydration.
Study Started
Jul 31
2013
Primary Completion
Feb 28
2014
Study Completion
Apr 30
2014
Results Posted
Dec 16
2016
Estimate
Last Update
Dec 16
2016
Estimate

Drug 0.3% Saline in 3.3% dextrose

Hypotonic Solutions: 0.3% Saline in 3.3% dextrose

  • Other names: Hypotonic Solutions: 0.3% Saline + 3.3% dextrose

Drug 0.45% Saline in 5% dextrose

Hypotonic Solutions: 0.45% Saline in 5% dextrose

  • Other names: Hypotonic Solutions: 0.45% Saline in 5% dextrose

Drug 0.9% Saline in 5% dextrose

Isotonic Solutions 0.9% Saline in 5% dextrose

  • Other names: Isotonic Solutions 0.9% Saline in 5% dextrose

Group 1: 0.3% Saline in 3.3% dextrose (intravenous) Active Comparator

Group 1: 0.3% Saline in 3.3% dextrose (intravenous)

Group 2: 0.45% Saline in 5% dextrose (intravenous) Active Comparator

Group 2: 0.45% Saline in 5% dextrose (intravenous)

Group 3: 0.9% Saline in 5% dextrose (intravenous) Active Comparator

Group 3: 0.9% Saline in 5% dextrose (intravenous)

Criteria

Inclusion Criteria:

Children between 3 months to 15 years.
Need for intravenous fluids for 8 hours or more.
Normal serum sodium at the beginning of the study of the study (135-145 mEQ/L).
Acute respiratory problems (acute asthma attack, bronchiolitis or pneumonia).
Acute gastrointestinal disorders (viral o bacterial gastroenteritis).
Elective surgical procedures.
Pre, peri o post operative patients (acute appendicitis, intussusception, intestinal perforation, ileus).

Exclusion Criteria:

Severe hyponatremia (serum sodium < 125 mEq/L).
Severe hypernatremia (serum sodium >155 mEq/L).
Need for intravenous fluids for less than 8 hours according with their treating physician.
Severe dehydration or Shock.
Preexisting chronic diseases (renal diseases, heart diseases or endocrine disorders).
Neurologic diseases.
Head trauma.
Cerebral edema or Intracranial hypertension.
Diabetic ketoacidosis.
Use of diuretics one week or less before the study.
Need for admission to the pediatric critical intensive care unit

Summary

Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous)

Group 2: 0.45% Saline in 5% Dextrose (Intravenous)

Group 3: 0.9% Saline in 5% Dextrose (Intravenous)

All Events

Event Type Organ System Event Term Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous) Group 2: 0.45% Saline in 5% Dextrose (Intravenous) Group 3: 0.9% Saline in 5% Dextrose (Intravenous)

Hospital Acquired Hyponatremia

Serum sodium less than 135 mEq/L at 8 hours in a patient with normal serum sodium (135 mEq/L to 145mEq/L) at the beginning of the study

Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous)

10.0
participants

Group 2: 0.45% Saline in 5% Dextrose (Intravenous)

11.0
participants

Group 3: 0.9% Saline in 5% Dextrose (Intravenous)

1.0
participants

Dysnatraemias at T8

hyponatraemia (defined as serum sodium < 135 mmol/L), normonatremia (defined as serum sodium 135-145 mmol/L) or hypernatraemia (defined as serum sodium > 145 mmol/L)

Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous)

Hypernatremia

Hyponatremia

23.0
participants

Normonatremia

26.0
participants

Group 2: 0.45% Saline in 5% Dextrose (Intravenous)

Hypernatremia

Hyponatremia

20.0
participants

Normonatremia

30.0
participants

Group 3: 0.9% Saline in 5% Dextrose (Intravenous)

Hypernatremia

2.0
participants

Hyponatremia

3.0
participants

Normonatremia

47.0
participants

Adverse Reactions Attributed to Acute Plasma Sodium Changes

Adjudicated Morbidity Attributed to Acute Plasma Sodium Changes assessed at 8 hours

Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous)

12.0
Minor Adverse Reactions

Group 2: 0.45% Saline in 5% Dextrose (Intravenous)

13.0
Minor Adverse Reactions

Group 3: 0.9% Saline in 5% Dextrose (Intravenous)

11.0
Minor Adverse Reactions

Total

151
Participants

Age, Continuous

58.9
months (Mean)
Standard Deviation: 56.5

Dehydration (mild), n

33
participants

Heart rate, bpm

126
bpm (Mean)
Standard Deviation: 27

Hypernatremic, n

2
participants

Hyponatraemia, n

51
participants

Normonatremic, n

98
participants

Serum osmolarity, mOsm/L

279
mOsm/L (Mean)
Standard Deviation: 8.6

Serum sodium, mmol/L

135.5
mmol/L (Mean)
Standard Deviation: 3

Systolic blood pressure, mmHg

100.1
mmHg (Mean)
Standard Deviation: 10.5

Sex: Female, Male

Overall Study

Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous)

Group 2: 0.45% Saline in 5% Dextrose (Intravenous)

Group 3: 0.9% Saline in 5% Dextrose (Intravenous)

Drop/Withdrawal Reasons

Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous)

Group 2: 0.45% Saline in 5% Dextrose (Intravenous)

Group 3: 0.9% Saline in 5% Dextrose (Intravenous)